title: Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers.
abstract: Breast cancer is second most prevalent cancer in women, and the second only to lung cancer in cancer-related deaths. It is a heterogeneous disease and has several subtypes based on the presence or absence of hormone receptors and/or human epidermal growth factor receptor 2 (HER2). Hormone receptor-positive and HER2-enriched cancers can be targeted using hormone and HER2-targeting therapies such as trastuzumab or lapatinib. However, triple-negative breast cancers (TNBCs) do not express any of the receptors and therefore are resistant to most targeted therapies, and cytotoxic chemotherapies are the only viable option available for the treatment of TNBCs. Recently, cardiac glycosides (CGs) have emerged as potential anticancer agents that impart their antiproliferative effect by targeting multiple pathways. In this study our aim was to evaluate anticancer effects of two naturally occurring CGs, Convallatoxin (CT) and Peruvoside (PS), on ER+ and TNBCs cells. CT and PS demonstrated dose- and time-dependent cytotoxic effect on MCF-7 cells, which was further supported by loss of colony formation on drug treatment. CT and PS arrested MCF-7 cells in the G0/G1 phase and reduced the viability of MCF-7-derived mammospheres (MMs). Interestingly, while CT and PS imparted cell death in TNBCs cells from both Caucasians (MDA-MB-231 cells) and African Americans (MDA-MB-468 cells) in a dose- and time-dependent manner, the drugs were much more potent in MDA-MB-468 as compared with TNBC MDA-MB-231 cells. Both drugs significantly inhibited migration and invasion of both MCF-7 and MDA-MB-468 cells. An assessment of intracellular pathways indicated that both drugs were able to modulate several key cellular pathways such as EMT, cell cycle, proliferation and cell death in both cell types. Our data suggest a promising role for CGs in breast cancer treatment specifically in targeting TNBCs derived from African Americans, and provides impetus for further investigation of the anticancer potential of this class of drugs.
authors.affiliation: Department of Pharmaceutical Sciences, Hampton University School of Pharmacy , Kittrell Hall, Queen & Tyler Streets, Hampton, VA 23668, USA.
authors.forename: Vivek
authors.initials: V
authors.lastname: Kaushik
authors.affiliation: Department of Pharmaceutical Sciences, Hampton University School of Pharmacy , Kittrell Hall, Queen & Tyler Streets, Hampton, VA 23668, USA.
authors.forename: Neelam
authors.initials: N
authors.lastname: Azad
authors.affiliation: Department of Pharmaceutical Sciences, Hampton University School of Pharmacy , Kittrell Hall, Queen & Tyler Streets, Hampton, VA 23668, USA.
authors.forename: Juan Sebastian
authors.initials: JS
authors.lastname: Yakisich
authors.affiliation: Department of Pharmaceutical Sciences, Hampton University School of Pharmacy , Kittrell Hall, Queen & Tyler Streets, Hampton, VA 23668, USA.
authors.forename: Anand Krishnan V
authors.initials: AK
authors.lastname: Iyer